Linked e-resources
Details
Table of Contents
The three-decade long journey in heart failure drug development / Kelly S. Lewis, Javed Butler, Johann Bauersachs, Peter Sandner
Epidemiology of heart failure / Francesco Orso, Gianna Fabbri, Aldo Pietro Maggioni
Comorbidities in heart failure / Haye H. van der Wal, Vincent M. van Deursen, Peter van der Meer, Adriaan A. Voors
Clinical trial design, endpoints, and regulatory requirements / Giuseppe M. C. Rosano
Biomarkers of heart failure with preserved and reduced ejection fraction / Michele Senni, Emilia D'Elia, Michele Emdin, Giuseppe Vergaro
Heart failure guidelines on pharmacotherapy / Lampros Papadimitriou, Carine E. Hamo, Javed Butler
Sacubitril/valsartan (LCZ696) in heart failure / Yasser Khder, Victor Shi, John J. V. McMurray, Martin P. Lefkowitz
Ivabradine / Michel Komajda
Partial adenosine A1 agonist in heart failure / Wilfried Dinh, Barbara Albrecht-Küpper, Mihai Gheorghiade, Adriaan A. Voors [and others]
New and emerging therapies and targets: beta-3 agonists / Lauriane Y. M. Michel, Jean-Luc Balligand
Novel SGC stimulators and SGC activators for the treatment of heart failure / Stefanie Breitenstein, Lothar Roessig, Peter Sandner, Kelly S. Lewis
Cardiac phosphodiesterases and their modulation for treating heart disease / Grace E. Kim PhD, David A. Kass MD
Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside / Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack [and others]
Vasopressin and vasopressin antagonists in heart failure / Julie K. Vishram-Nielsen, Finn Gustafsson
Mesenchymal stem cell therapy for the treatment of heart failure caused by ischemic or non-ischemic cardiomyopathy: immunosuppression and its implications / Michael J. Lipinski, Dror Luger, Stephen E. Epstein
Platelet-derived growth factor in heart failure / John Medamana, Richard A. Clark, Javed Butler
Wnt signaling in cardiac remodeling and heart failure / Vasili Stylianidis, Kevin C. M. Hermans, W. Matthijs Blankesteijn
Gene therapy in heart failure / Anthony S. Fargnoli, Michael G. Katz, Charles R. Bridges, Roger J. Hajjar
Noncoding RNAs in heart failure / Seema Dangwal, Katharina Schimmel, Ariana Foinquinos, Ke Xiao, Thomas Thum
Cardiac myosin activation with gene therapy produces sustained inotropic effects and may treat heart failure with reduced ejection fraction / Sam L. Teichman, Kassandra S. Thomson, Michael Regnier.
Epidemiology of heart failure / Francesco Orso, Gianna Fabbri, Aldo Pietro Maggioni
Comorbidities in heart failure / Haye H. van der Wal, Vincent M. van Deursen, Peter van der Meer, Adriaan A. Voors
Clinical trial design, endpoints, and regulatory requirements / Giuseppe M. C. Rosano
Biomarkers of heart failure with preserved and reduced ejection fraction / Michele Senni, Emilia D'Elia, Michele Emdin, Giuseppe Vergaro
Heart failure guidelines on pharmacotherapy / Lampros Papadimitriou, Carine E. Hamo, Javed Butler
Sacubitril/valsartan (LCZ696) in heart failure / Yasser Khder, Victor Shi, John J. V. McMurray, Martin P. Lefkowitz
Ivabradine / Michel Komajda
Partial adenosine A1 agonist in heart failure / Wilfried Dinh, Barbara Albrecht-Küpper, Mihai Gheorghiade, Adriaan A. Voors [and others]
New and emerging therapies and targets: beta-3 agonists / Lauriane Y. M. Michel, Jean-Luc Balligand
Novel SGC stimulators and SGC activators for the treatment of heart failure / Stefanie Breitenstein, Lothar Roessig, Peter Sandner, Kelly S. Lewis
Cardiac phosphodiesterases and their modulation for treating heart disease / Grace E. Kim PhD, David A. Kass MD
Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside / Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack [and others]
Vasopressin and vasopressin antagonists in heart failure / Julie K. Vishram-Nielsen, Finn Gustafsson
Mesenchymal stem cell therapy for the treatment of heart failure caused by ischemic or non-ischemic cardiomyopathy: immunosuppression and its implications / Michael J. Lipinski, Dror Luger, Stephen E. Epstein
Platelet-derived growth factor in heart failure / John Medamana, Richard A. Clark, Javed Butler
Wnt signaling in cardiac remodeling and heart failure / Vasili Stylianidis, Kevin C. M. Hermans, W. Matthijs Blankesteijn
Gene therapy in heart failure / Anthony S. Fargnoli, Michael G. Katz, Charles R. Bridges, Roger J. Hajjar
Noncoding RNAs in heart failure / Seema Dangwal, Katharina Schimmel, Ariana Foinquinos, Ke Xiao, Thomas Thum
Cardiac myosin activation with gene therapy produces sustained inotropic effects and may treat heart failure with reduced ejection fraction / Sam L. Teichman, Kassandra S. Thomson, Michael Regnier.